Virax Biolabs Group Limited (VRAX)Healthcare | Biotechnology | Lanarkshire, United Kingdom | NasdaqCM
2.82 USD
-0.12
(-4.082%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.80 -0.02 (-0.020%) ⇩ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:06 a.m. EDT
The immediate outlook is severely clouded by a catastrophic multi-year price collapse. Despite a recent technical bounce, the stock has lost over 98% of its value over the last three years, with the most recent annual period showing an 85% drop. This deep structural deterioration, combined with negative earnings, massive operating losses, and a negative forward P/E, suggests the market has priced out the business entirely. The recent news of share consolidation and rising short interest confirms that investors are fleeing the asset rather than finding value in it. With no dividend to provide income and a balance sheet showing significant free cash flow burn, there is no safety margin here. The statistical forecast model offers virtually no guidance due to extreme volatility, reinforcing the view that this is a speculative gamble rather than an investment opportunity. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.107046 |
| AutoETS | 0.127021 |
| AutoTheta | 0.127766 |
| MSTL | 0.143113 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 20% |
| H-stat | 0.13 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 6.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.649 |
| Revenue per Share | 0.031 |
| Market Cap | 2,247,506 |
| Forward P/E | -0.47 |
| Beta | 1.34 |
| Website | https://viraxbiolabs.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.79404557 |
| Address1 | BioCity Glasgow |
| Address2 | Bo’Ness Road Newhouse |
| All Time High | 7,250.0 |
| All Time Low | 2.5 |
| Ask | 3.31 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 1,909,910 |
| Average Daily Volume3 Month | 1,824,627 |
| Average Volume | 1,852,184 |
| Average Volume10Days | 1,909,910 |
| Beta | 1.337 |
| Bid | 2.46 |
| Bid Size | 1 |
| Book Value | 13.082 |
| City | Lanarkshire |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.82 |
| Current Ratio | 9.968 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.945 |
| Day Low | 2.77 |
| Debt To Equity | 5.649 |
| Display Name | Virax Biolabs |
| Ebitda | -6,048,149 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.779 |
| Enterprise To Revenue | -379.363 |
| Enterprise Value | -4,712,824 |
| Eps Current Year | -6.0 |
| Eps Forward | -6.0 |
| Eps Trailing Twelve Months | -12.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3001 |
| Fifty Day Average Change | -0.48010015 |
| Fifty Day Average Change Percent | -0.14548048 |
| Fifty Two Week Change Percent | -80.59406 |
| Fifty Two Week High | 21.75 |
| Fifty Two Week High Change | -18.93 |
| Fifty Two Week High Change Percent | -0.8703448 |
| Fifty Two Week Low | 2.5 |
| Fifty Two Week Low Change | 0.31999993 |
| Fifty Two Week Low Change Percent | 0.12799998 |
| Fifty Two Week Range | 2.5 - 21.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,658,410,200,000 |
| Float Shares | 529,040 |
| Forward Eps | -6.0 |
| Forward P E | -0.47 |
| Free Cashflow | -3,477,016 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 26 |
| Fullday Change | -0.12 |
| Fullday Change Percent | -4.08164 |
| Fullday Price | 2.8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.61901003 |
| Gross Profits | 7,690 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02623 |
| Held Percent Institutions | 0.03311 |
| Implied Shares Outstanding | 796,988 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-07-21 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Last Split Date | 1,782,432,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom. |
| Long Name | Virax Biolabs Group Limited |
| Market | us_market |
| Market Cap | 2,247,506 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1685878340 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -5,023,750 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 2,343,144 |
| Number Of Analyst Opinions | 1 |
| Open | 2.895 |
| Operating Cashflow | -4,621,892 |
| Operating Margins | -352.64923 |
| Payout Ratio | 0.0 |
| Phone | 44 20 7788 7414 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.7092192 |
| Post Market Price | 2.8 |
| Post Market Time | 1,787,961,590 |
| Previous Close | 2.94 |
| Price Eps Current Year | -0.47 |
| Price Hint | 4 |
| Price To Book | 0.21556337 |
| Price To Sales Trailing12 Months | 180.91492 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.555 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.120000124 |
| Regular Market Change Percent | -4.0816364 |
| Regular Market Day High | 2.945 |
| Regular Market Day Low | 2.77 |
| Regular Market Day Range | 2.77 - 2.945 |
| Regular Market Open | 2.895 |
| Regular Market Previous Close | 2.94 |
| Regular Market Price | 2.82 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 35,714 |
| Return On Assets | -0.54229 |
| Return On Equity | -0.78646004 |
| Revenue Growth | 6.849 |
| Revenue Per Share | 0.031 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 796,988 |
| Shares Percent Shares Out | 0.0293 |
| Shares Short | 23,357 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 25,046 |
| Short Name | Virax Biolabs Group Limited |
| Short Percent Of Float | 0.0301 |
| Short Ratio | 0.04 |
| Source Interval | 15 |
| Symbol | VRAX |
| Target High Price | 25.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 25.0 |
| Target Median Price | 25.0 |
| Total Cash | 6,518,205 |
| Total Cash Per Share | 11.253 |
| Total Debt | 414,387 |
| Total Revenue | 12,423 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -12.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.81565 |
| Two Hundred Day Average Change | -2.99565 |
| Two Hundred Day Average Change Percent | -0.5151015 |
| Type Disp | Equity |
| Volume | 35,714 |
| Website | https://viraxbiolabs.com |
| Zip | ML1 5UH |